Publications by authors named "A Ardavanis"
Background/aim: Everolimus in combination with exemestane was shown to offer benefit versus exemestane monotherapy in hormone receptor (HR)-positive, HER2-negative advanced breast cancer patients who progressed after aromatase inhibitor (AI) therapy.
Patients And Methods: The medical records of metastatic breast cancer patients, treated with everolimus, were retrospectively reviewed to generate real life safety and efficacy data.
Results: Sixty-eight percent of the patients had received chemotherapy (for early or metastatic disease) and 26% had received chemotherapy for metastatic disease.
Exploring the Use of a Digital Platform for Cancer Patients to Report Their Demographics, Disease and Therapy Characteristics, Age, and Educational Disparities: An Early-Stage Feasibility Study.
Curr Oncol
August 2023
Article Synopsis
- - The study aimed to evaluate the feasibility of the CureCancer platform for Greek cancer patients, focusing on their ability to register and report various personal and health-related information amid increasing cancer care complexity due to new treatments and the COVID-19 pandemic.
- - Out of 159 invited patients, 144 registered (90.56%), and 114 completed the questionnaire (79.16%), indicating a strong interest and ease of use among participants; most were educated individuals with a median age of 54.5 years.
- - The demographics revealed that a significant portion had breast and lung cancers, with many undergoing active therapy, highlighting the diverse cancer experiences and reporting trends of those participating in the study.
Article Synopsis
- A European registry was established for patients with advanced EGFR exon 20-mutant non-small cell lung cancer (NSCLC) diagnosed between January 2019 and December 2021, specifically excluding those enrolled in clinical trials.* -
- The final analysis included data from 175 patients across nine countries, revealing a median age of 64 years, predominantly affecting women (56.3%) and mostly comprising adenocarcinoma cases (95.4%) with frequent bone (47.4%) and brain (32.0%) metastases.* -
- Treatment patterns varied significantly: chemotherapy and chemotherapy-immunotherapy combinations were used in 33.8% and 18.2% of cases respectively, with disease control rates of
Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical models. The anti-angiogenic drug cabozantinib was tested in a phase 2 trial of advanced OS and ES and was associated with clinical benefits.
View Article and Find Full Text PDFAcquired immune resistance (AIR) describes a situation in which cancer patients who initially responded clinically to immunotherapies, after a certain period of time, progress with their disease. Considering that AIR represents a feedback response of the tumor against the immune attack generated during the course of immunotherapies, it is conceivable that AIR may also occur before treatment initiation as a mechanism to escape endogenous adaptive antitumor immunity (EAAI). In the present study, we assessed the EAAI in paraffin-embedded breast primary tumor tissue samples and drew correlations with the clinical outcomes.
View Article and Find Full Text PDF